

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Brady Todd C</u>	2. Date of Event Requiring Statement (Month/Day/Year) 05/01/2014	3. Issuer Name and Ticker or Trading Symbol <u>Aldeyra Therapeutics, Inc. [ALDX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President and CEO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) <u>C/O ALDEYRA THERAPEUTICS, INC.</u> <u>15 NEW ENGLAND EXECUTIVE PARK</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>BURLINGTON MA</u> <u>01803</u>			
(City) (State) (Zip)			

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>2,589</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Employee Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>09/07/2023</u>	<u>Common Stock</u>	<u>192,084</u>	<u>0.552</u>	<u>D</u>
<u>Employee Stock Option (Right to Buy)</u>	<u>(2)</u>	<u>09/07/2023</u>	<u>Common Stock</u>	<u>32,953</u>	<u>0.552</u>	<u>D</u>
<u>Employee Stock Option (Right to Buy)</u>	<u>(3)</u>	<u>09/07/2023</u>	<u>Common Stock</u>	<u>48,021</u>	<u>0.552</u>	<u>D</u>
<u>Employee Stock Option (Right to Buy)</u>	<u>(4)</u>	<u>10/29/2023</u>	<u>Common Stock</u>	<u>96,042</u>	<u>4.56</u>	<u>D</u>

Explanation of Responses:

- Exercisable over four years of service from April 15, 2013, with 25% vesting upon completion of 12 months of service and in 36 equal monthly installments thereafter.
- This option became exercisable with respect to 1/6th of the shares each month over six months of continuous service following April 1, 2013.
- Exercisable with respect to 16,007 shares upon each of the effective date of the initial public offering, the date on which the Issuer's closing market capitalization equals at least \$55.0 million for 10 consecutive trading days and the date on which the Issuer's closing market capitalization equals at least \$70.0 million for 10 consecutive trading days, provided that Dr. Brady remains in continuous service with the Issuer through each such date.
- Exercisable with respect to 1/16th of the shares in quarterly installments over four years of continuous service following October 30, 2013.

Remarks:

/s/ Todd C. Brady05/01/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.